Common
Intismeran autogene
MRNA-based cancer vaccine
Intismeran autogene
Intismeran autogene (previously known by its investigational drug name mRNA-4157/V940) is an mRNA based cancer vaccine encapsulated in solid lipid nanoparticles. The 34 mRNA sequences in mRNA-4157/V940 vaccine were generated by an automated algorithm integrated with workflow based on massive parallel sequencing of tissue generated from cancer patients. As adjuvant therapy, mRNA-4157 monotherapy and in combination with pembrolizumab have been investigated in patients with resected solid tumors (melanoma, bladder carcinoma, HPV negative HNSCC, NSCLC, SCLC, MSI-high, or TMB-high cancers). It was also investigated in patients with HNSCC and MSS-CRC.
Open boosters, collect cards and trade them. Free to play.
Play for free